



Addressing Unhealthy Substance Use in Primary Care

Richard Saitz, MD, MPH, FACP, FASAM Professor of Medicine & Epidemiology Boston University Schools of Medicine & Public Health Boston Medical Center



Outline

- Primary care...
 - Screening for unhealthy substance use in primary care
 - Brief intervention
 - Behavioral and pharmacological interventions
- Substance dependence as a chronic disease
- Co-occurring conditions
- Chronic care/disease management
 - Example

Does unhealthy substance use meet criteria for universal screening?

- Significant morbidity/mortality?
- High prevalence?
- Asymptomatic period during which detection can occur?
- Valid, feasible screening test?
- Early intervention better (than later)(screening and intervention versus not)?

Unhealthy Substance Use is Common

 • 28% of adults have unhealthy alcohol use (drink too much), 8.5% of adults have alcohol use disorder

•8% of adults use illicit drugs (MJ, NMUPD most common)

•In adult primary care...

•Current unhealthy alcohol 8% (HMO) to 22-28%

Approx. 40% at-risk, 40% problem, 20% dependent
Current drug use 3% (HMO) to 5%

Grant BF et al. Drug Alcohol Dep 2004;74:223, Mertens J et al. ACER 2005, Manwell et al. J Addictive Dis 1998, NESARC 2003

Practice Guideline

• The U.S. Preventive Services Task Force (USPSTF) recommends screening and behavioral counseling interventions to reduce alcohol misuse by adults, including pregnant women, in primary care settings.



OFFICE OF NATIONAL DRUG CONTROL POLICY

2008 White House Leadership Summit on Screening and Brief Intervention (SBI) for Substance Abuse

FRIDAY, SEPTEMBER 5, 2008 • 9:00 AM - 3:00 PM

This is a grade B recommendation (at least fair evidence of improved health outcomes and that benefits outweigh harm). USPSTF. *Ann Intern Med* 2004; 140: 554-6.

CLINICAL GUIDELINES

Screening and Behavioral Counseling Interventions in Primary Care To Reduce Alcohol Misuse: Recommendation Statement

U.S. Primeetine Services Task Force"

This observed summanians the U.S. Proversion Samion. Task in each (USPT) is commandiated on the bistories of company distributions of the second seco

alie timugt the USPE Web tile convergenceritesentiscultquye). The journal article and the USPET scornwendators dutament are available in polit timugh the Agency for Healthcare Research and Quality Publications Gain agicons (Healthcare 28-9056, e-mit, Arappatoistinggor).

SUMMARY OF THE RECOMMENDATIONS

The U.S. Prevening and behaviour Tath Force (USISTF) recommends according to behaviour dominating interventions to reduce alcohol mission (see Christal Camidoation) by adules, including program worsen, in prinary care sering. This is a grade to recommondation (See Appender Table 1 for a description of the USISTF daskcition of recommondations).

The USPSTF found good evidence that unreading in primary care senting can accurately identify patients where loads sufficient to down the parential benefits and barron of sevening and behavioral controlling interventions in the population.

CUNCAL CONSIDERATIONS

Alcohol minuse includes "rishy/hazardoss" and "harmfal" drinking that places individuals at rish for fasture problems. "Rishy" or "hazardoss" drinking har been defined in the United Status as more than 7 drinks per week to more

US Preventive Services Task Force

- Evidence limited to treatment seeking populations; insufficient evidence to change recommendation
- "The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening adolescents, adults, and pregnant women for illicit drug use." (Jan 2008)

AMA <u>CPT codes</u>

99408 Alcohol and/or substance (other than tobacco) abuse

structured screening and brief intervention services; 15-30" 99409 > 30 minutes

Modifier -25 may be coded for some health plans. Separate and distinct from all other E&M services.

CMS codes (for <u>Medicare</u> fee-for-service patients) G0396 Alcohol and/or substance (other than tobacco) abuse structured assessment, and brief intervention (SBI) services; 15 to 30 minutes. G0397 > 30 minutes

CMS codes for <u>Medicaid</u> (need to be "turned on")
H0049 Alcohol and/or drug screening.
H0050 Alcohol and/or drug services, brief intervention, per 15 minutes.

AMA Physician Consortium for Performance Improvement (PCPI) measure: alcohol screeningAMA CPT2 tracking codes (incentive \$...)(coming in 2009)

Screen for what?


- Drug use
- Unhealthy alcohol use

Amounts that risk health consequences


– Men

- >14 standard drinks per week
- >4 per occasion
- Women, ≥ 65
 - >7 per week
 - >3 per occasion





The Spectrum of Alcohol Use



Saitz, R. N Engl J Med 2005;352:596-607



The NEW ENGLAND

IOURNAL of MEDICINE

Screening Tests

- Best choices all around
 - 1 for alcohol, 1 for drug
 - DRUG
 - Single-item
 - ALCOHOL
 - Single-item (episodic limit)
 - AUDIT-C
 - AUDIT
 - CAGE+consumption

- Other choices (some limits)
 - ASSIST
 - CAGE
 - CRAFFT (adolescents)
 - POSIT (adolescents)
 - TWEAK (pregnancy)
 - T-ACE (pregnancy)
 - MAST
 - B-MAST, S-MAST, G-MAST
 - DAST-10
 - AUDIT-R
 - CAGE-AID
 - 2-item conjoint
 - Consensus single item (CSAT)
 - Laboratory tests
 - Hair, saliva, urine, serum
 - BAC, CDT, GGT, AST, HDL, MCV

'Single' Item

- NIAAA: "Do you sometimes drink beer wine or other alcoholic beverages? How many times in the past year have you had 5 (4 for women) or more drinks in a day?"*
 - +answer:>0
 - 82% sensitive, 79% specific

*NIAAA. Clinicians Guide to Helping Patients Who Drink Too Much, 2007. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Alcohol Clin Exp Res 2007; 22(Suppl 1):108. **Williams & Vinson. J Fam Pract 2001;50:307.

Screening Tests

- Best choices all around
 - 1 for alcohol, 1 for drug
 - DRUG
 - Single-item
 - ALCOHOL
 - Single-item (episodic limit)
 - AUDIT-C
 - AUDIT
 - CAGE+consumption

- Other choices (some limits)
 - ASSIST
 - CAGE
 - CRAFFT (adolescents)
 - POSIT (adolescents)
 - TWEAK (pregnancy)
 - T-ACE (pregnancy)
 - MAST
 - B-MAST, S-MAST, G-MAST
 - DAST-10
 - AUDIT-R
 - CAGE-AID
 - 2-item conjoint
 - Consensus single item (CSAT)
 - Laboratory tests
 - Hair, saliva, urine, serum
 - BAC, CDT, GGT, AST, HDL, MCV

Single Item drug screening

- "How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?"
 - If asked to clarify the meaning of "non-medical reasons", add "for instance because of the experience or feeling it caused"
 - a response of ≥ 1 is considered positive
 - 100% sensitive, 73.5% specific for drug use disorder, similar to 10-item DAST
 - 92.9% and 94.1% for past-year drug use

Smith P et al. 2008 abstract



Assess for risky use and consequences

- Determine risks
 - Use in high risk situations, with medications that can interact or contraindicated medical (eg sleep, liver disease, hypertension, injury) or mental health conditions (eg depression), pregnancy, personal or family history
- Determine whether your patient's drinking has repeatedly caused or contributed to
 - risk of bodily harm (drinking and driving, operating machinery, swimming)
 - relationship trouble (family or friends)
 - role failure (interference with home, work, or school obligations)
 - run-ins with the law (arrests or other legal problems)



Assess for dependence symptoms

- Impaired control/Preoccupation
 - A great deal of time getting, using, recovering
 - Activities given up or reduced
 - More or longer than intended
 - Cannot cut down or control
 - Use despite knowledge of health problem
- Withdrawal
 - Symptoms, using to relieve symptoms
- Tolerance
 - Increased amounts to achieve effect
 - Diminished effect from same amount

Brief *assessment* for alcohol use disorders Presence of either: Recurrent drinking in physically hazardous situations or Drinking more or for longer than intended.

	Sensitivity	Specificity
Screen-positive subjects in 3 validation samples	77% to 95%	62% to 86%

Vinson DC et al. Alcohol Clin Exp Res. 2007;31(8):1392–1398.

Ingredients of Successful Brief Interventions • What? • How? -10-15 minutes -Empathy -Feedback -Self-efficacy -Advice -Menu -Goal Setting -Follow-up Learn via video cases. Free at:

www.niaaa.nih.gov (Clinician's Guide) and www.mdalcoholtraining.org

Example

- Feedback: 'The amounts you are drinking are above recommended limits and put your health at risk. Your use of alcohol may be interfering with your sleep. What do you think of that?'
- Advice: 'Would you like to hear my advice about this? My best medical advice is that you cut back...This may help your sleeping and will help avoid other problems in the future.'

Efficacy of Brief Intervention

- Proportion of drinkers of risky amounts lower one year after brief intervention (69% vs. 57%)(n=2784)
- Consumption decreased 15% more than without brief intervention (by 38 grams [about 3 standard drinks] per week)(n=5639)

Meta-analyses: Beich et al. BMJ 2003;327:536 Bertholet et al. Arch Intern Med. 2005;165:986

Treatment in Medical Settings: TrEAT Study

- RCT, 17 practices, 64 physicians
- N=774
 - Men >14 drinks/wk
 - Women >11 drinks/wk
- 93% 12 month follow-up
- Control: health booklet
- Intervention: health booklet + 2 10-15" physician discussions and a follow-up nurse phone call

Fleming MF, Lawton Barry K, et al. JAMA 1997;277:1039

TrEAT Study Results

	Control	Intervention
	before/after	before/after
Drinks/7d*	19/16 (-18%)	19/12 (-40%)
Binges/30d*	5/4 (-21%)	6/3 (-46%)
Hosp days*	42/146 (+248%)	93/91 (-1%)
*p<0.001		

Fleming MF, Lawton Barry K, et al. JAMA 1997;277:1039

Efficacy and Cost of Advice TrEAT Long-term Follow-up

At 4 years	Control	Intervention		
Hospital Days (p<0.05)	663	420		
ED Visits (p<0.08)	376	302		
Risky Drinking* (p<0.001)	35%	23%		
Cost of intervention: \$166 per patient (includes patient costs)				
Net benefit: \$546 in medical costs, \$7780 if societal costs included (mainly motor vehicle)				

*36 months. >20 drinks (men), >13 drinks (women) per week Fleming MF et al. Alcohol Clin Exp Res. 2002;26(1):36-43.

The Malmö Study

- Population-based cohort of middle-aged men identified by screening with upper decile GGT as isolated abnormality and at least 20 g alcohol daily
- Randomized to
 - GGT + RN q mo, MD q 3 mo
 - letter—GGT is high, restrict alcohol, F/U in 2 years
- 78% follow-up (4 years)

Kristenson H, et al. Alcohol Clin Exp Res 1983;7:203

The Malmö Study

- 5-year hospital utilization decreased by 50% in 5 years (total approx. 1600 vs 800 days, mainly alcoholrelated)
- Sick days decreased in intervention group
- **GGT** decreased in both groups (4 yrs)
- 16-year mortality decreased in intervention group
 <u>– Total mortality: 10% vs. 14% (NS)</u>
 - Alcohol-related (48% of all deaths): 4% vs. 7% (p=0.03)

Kristenson H, et al. Alcohol Clin Exp Res 1983;7:203

3 controlled studies of Drug BI in people identified by screening

- Small study of adolescents in primary care in Sao Paulo
 - Positive study (decreased ecstasy and MJ use and drug problems) but only 59 subjects
- Bernstein et al, in outpatients (not primary care)
- WHO ASSIST trial

Drug SBI in outpatients - RCT

- 23,660 patients screened (DAST) in women's health, homeless, and urgent care clinics.
- 1,175 with risky heroin or cocaine use (DAST ≥3) randomized to brief negotiated interview (BNI) or referral list/written advice; 82% completed 6-month follow-up.
- 6-month abstinence (hair)
 - Opiates: 40% of BNI, 31% of control
 - Cocaine: 22% of BNI, 17% of control
- About 38% of subjects reported a contact with drug treatment (no difference)

Bernstein et al. Drug Alcohol Dep January 2005

Drug SBI in Primary Care

- RCT
- N=731 with current drug use identified using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST); sexually transmitted disease clinics, walk-in clinics, a dental clinic, and community medical care sites in 4 countries.
- Patients with moderate-risk scores randomly assigned to BI or no BI (low- or high-risk range excluded).

Humeniuk R, et al. Technical Report of Phase III Findings of the WHO ASSIST Randomized Controlled Trial. Geneva, Switzerland: WHO, 2008.

ASSIST Trial Results

- BI (vs. no BI) associated with a 3-point greater decrease in a substance use score (max score 336).
- Cannabis and stimulant scores also decreased more for BI subjects (by about 2–3 points on scales with a maximum of 39 points); opioid scores did not.
- Substance use was not significantly impacted by BI in the US.

Primary Care Management of Substance Dependence

- Menu of options (including referral)
 - Withdrawal management or referral (for opioids, severity)
 - Medications and brief, ongoing counseling
 - Assess and address any psychiatric comorbidity
 - Mutual help groups (NA, AA)
 - Needle exchange
 - Specialty outpatient counseling
- Follow-up and relapse prevention once in recovery
 - Help patient anticipate difficult situations (triggers)
 - Emphasize prior successes and use relapse as a learning experience, cope w/craving
 - Ask patient about plans to manage early relapses (lapses)

Friedmann PD, Saitz R, Samet JH. JAMA 1998;279(15):1227-31.

Alcohol Treatment Outcomes

- At one year, 2/3^{rds} of patients have a reduction in
 - alcohol consequences (e.g. injury, unemployment)
 - consumption (by about 50%)
 - 1/3rd are abstinent or drinking moderately without consequences

Miller WR et al. J Stud Alcohol 2001;62:211-20, Anon. Journal of Studies on Alcohol 1997;58:7-29, O'Brien CP, McLellan AT. Lancet 1996;347:237-240.

A word about "referral"

- Referral to specialty treatment and 12-step programs should be similar to other medical referrals, but it isn't
 - Solutions: knowledge about the treatment being referred to, the "warm hand-off"

Standard (FDA-approved) Medications for Alcohol and Drug Dependence

- 1. Disulfiram
- 2. Acamprosate
- 3. Naltrexone (drug/alcohol)
- 4. Methadone
- 5. Buprenorphine

Opioid Detoxification Outcomes

- Low rate of retention in treatment
- Low rate of achieving abstinence
- Low rates of success in maintaining abstinence
 - < 50% at 6 months
 - < 80% at 12 months</p>

JAMA 2005

In a Comprehensive Rehabilitation Program...*

- Increases overall survival
- Increases treatment retention
- Decreases illicit opioid use
- Decreases hepatitis and HIV seroconversion
- Decreases criminal activity
- Increases employment
- Improves birth outcomes

*Enhanced>Standard>no counseling McLellan et al JAMA 1993



Methadone Treatment Marks 40 Years

Bridget M. Kuehn

ORTY YEARS AND COUNTLESS Political firestorms after it was first introduced, methadone maintenance for the treatment of opioid addiction remains a standard therapy in the field of addiction treatment.

The publication on August 23, 1965, of positive results from a small clinical trial of methadone as a treatment for heroin addiction in *JAMA* marked a sea change in the treatment of addiction (Dole and Nyswander. *JAMA*. 1965; 193:646-650). The study, conducted at Rockefeller University in New York City by Vincent P. Dole, MD, and the late Marie E. Nyswander, MD, suggested that a medication could be used to control the cravings and withdrawal that often lead to relapse in individuals with opioid addiction who attempt to quit.

The work, along with subsequent research by Dole, an endocrinologist, Nyswander, a psychiatrist, and colleagues established the concept of opioid addiction as a chronic disease, similar to diabetes, that as such required now head of the Laboratory of the Biology of Addictive Diseases at Rockefeller University, explained that work conducted by the group in 1964 and published in 1966 established that methadone blocked the effects of heroin and stabilized patients, who prior to treatment oscillated between feeling



done treatment, the ap always struggled for accep the forces of public opini tics. "There is a stigma ap tions, addicts, and—sadly providers," said Kreek, a supporter of the methado

"THE FARM"

Methadone maintenance resented a reversal of the tr approach to treating dru said David F. Musto, MD turer at Yale and expert policy. A 1919 Supreme sion had established the alone did not justify physing addicts with opioids. B cision, some physicians has acting opioids to treat ind opioid addiction.

The Drug Enforcement tion, in fact, considered D illegal and had threatened him prior to the 1965 pub defy the US government wa litical courage," said Jeror who became the first natio

Relapse After Leaving Treatment




FIGURE 8.1. Relapse to intravenous drug use after methadone maintenance treatment for 105 male patients who left treatment. How long should methadone maintenance treatment last?

Long enough.

Methadone Maintenance Limitations

- Highly regulated Narcotic Addict Treatment Act 1974
 - Created methadone clinics (Opioid Treatment Programs)
 - Separate system not involving primary care or pharmacists
- Limited access
 - 5 states: 0 clinics, 4 states: < 3 clinics</p>
- Inconvenient and highly punitive
- Mixes stable and unstable patients
- Lack of privacy
- No ability to "graduate" from program
- Stigma

Opioid Medication Assisted Treatment Milestones

2000: Drug Addiction Treatment Act (DATA) 2000

 Allows <u>qualified physician</u> to prescribe <u>scheduled III -</u> <u>V</u>, narcotic <u>FDA approved</u> for opioid maintenance or detoxification treatment limit <u>30 patients per practice</u>

2002: Suboxone and Subutex FDA approved
2005: Limit to <u>30 patients per physician</u>
2007: Limit to <u>100 patients per physician</u> after 1 year


Physician Qualifications

Licensed physician is "qualified" based on <u>one</u> of the following:


- Certified in Addiction Psychiatry or Medicine
- Completed <u>eight hours</u> of training
 - List of trainings: www.buprenorphine.samhsa.gov
 - Online training:

BuprenorphineCME.com						
Home	Course List	Resources	Help	About Us	Contact Us	Sign Up Now!
		User Nam	ie 📃		Password	Login

Buprenorphine: Ceiling Effect



Effects of Buprenorphine Dose on mu Receptor Availability



Buprenorphine Efficacy


- Studies (RCT) show buprenorphine more effective than placebo and equally effective to moderate doses of methadone on primary outcomes of:
 - Abstinence from illicit opioid use
 - Retention in treatment
 - Decreased opioid craving

Johnson et al. NEJM 2000 Fudala PJ et al. NEJM 2003 Kakko J et al. Lancet 2003

Buprenorphine Summary

- Retention rates & efficacy comparable to methadone (80mg)
- "Ceiling" on opioid effects therefore low overdose risk
- Narcotic blockade
 - High affinity for opioid receptor
 - Slow dissociation from opioid receptor
- Abuse unlikely due to formulation w/ naloxone
 - Naloxone blocks opiate effect if injected
 - Naloxone is degraded (inert) if taking orally

Self-Reported Frequency of Illicit Opioid Use in Opioid-Dependent Patients Receiving Buprenorphine-Naloxone in Primary Care





Fiellin D et al. N Engl J Med 2006;355:365-374

and is not meant to be a substitute for the package inserts or other drug reference sources used by clinicians, the National Library of Medicine provides Medicine Plus **Alcohol medicatio** The factor on out a medication should be prescribed and in what amount is a matter between individuals incumstance, and the NIH accepts no flability or responsibility for use of the information with regard health care providers. The prescribing information provided here is not a substitute for a provider's individual circumstance, and the NIH accepts no liability or responsibility for use of the information with regard

Acamprosate (Campral®) Affects phramate and GABA neuronomittee

Anterus standardar land ondar ineuronalisationer Systems, but its alkohol related action is unchar

Severe read impairment $(G_1 G \leq 30 \text{ mL/min})$

Madsate read important (dose adjustment

To account to a maximum to account of the second of the se

or suicidality

Anxiety: depression. Rare events include the

Anany, repression, none armos answer non following: sociale attempt, acute kidney failure

han hive many in the same in t

rean vang trasmaa arom ocoori adomyspathy dep thombodiebits, ad

chile, somolence, decrement lidde, anner

No clinically relevant interactions known

Day state 666 mg (her 333 mg tablets) they tomer date ar for rations with nortaints and and the

times daily or for patients with moderate in

impointent (GCI 30-50 mL/min

333 mg (one tablet) the Before

-u 23 (see page 30)

Medications for Treating Alcohol Dependence

Contraindications Concontrant use of okohol on skohol-containing Contently using colouble on neuropacities on metroaddcale contaary atay withdowed anticipated used for agoid

epilepsy lightic distancial internation internation epilepsy lightic distancial internation internation international internatio

effects)

Oral dose: 50 mg daily

Followy: Monitor liver function tests

periodically

Before prescribing: Evaluate for possible current encre prescurge: channe to possible carent opioid: locg: cansiler a uniter to possible carent opioid: locking synthetic opioid: Obtain ther harrturn text.

epaepay, separa uputa nat, upanapatan tend inpaiment adder contact demantis

Hepatric and Deutity Desphered Aeuganty;

newars: unit newins: newars: newar

Metallic attertaste; dermatitis

Anitypythe anticappions such as variant

Annypowe: anacapana suu os manar dicepan soniarie nataailazole plenytan

harpon: bonco: nenonacco; nenonac harphiling: waton: ay nagascopio day

Dal dose 250 mg daily (range 125 mg to

Below percenting ()) want that patient should entropy press and a strain the process strains and process strains and process strains and process strains str dinking and that a disalifum dichol leachan

and (2) wan abast akabai in the des (ag. and (2) wan abast akabai in the des (ag. satures and vinegas) and in medkators and

The information in this chart was drawn primaria

Following: Monitor liver function tests

periodically

JULY 2005

Action

Precautions

Serious adverse

reactions

Common side effects

Examples of drug

interactions

Usual adult

dosage

The chart below highlights some of the properties of each medication. It does not provide complete information The chart below highlights some of the properties of each medication. It does not provide complete information about these and other drugs, the National Library of Medicine provides used by clinicians. For

Block opioid receptors, resulting in reduced

county and reduced reward in regulate to

withdowal anticipated need for good

Other hepotic disease in and impairment biology at an and and an and

Nauser, adaminal pair, constitution, dizoness. Damhar, flavolance, nauser, adaminal pair, constitution, dizoness. Damhar, flavolance, nauser, adaminal pair, haadache, kad pair, interline, fla sondarier, di sondarier, sont pair, interline, fla sont p

other nepone abeause rena mpamment of suicide attempts. If opioid analgesia is

required figher does nay be required and required, says score way to required, una regularity depression may be deeper and made

Will precipitate severe withdowal if patient is

dependent on opiolog, hepotoloxich (incommon on openas, regaringen of usual doses). Pegnancy

Category C.

Opioid analgesis (blocks action); yabimbine

and pesies acute hepatitis or liver failure

Primary care naltrexone

- RCT comparing primary care management (PCM, internist/nurse practitioner) and cognitive behavioral therapy (CBT, psychologist/psychiatrist)
 PCM was 15" weekly x 4 then biweekly x 6
 - CBT was 1 hour weekly x 12

Naltrexone RCT PCM vs. CBT			
	CBT	РСМ	p
	(n=97)	(n=93)	
Primary Outcomes			
<u><</u> 2 heavy drinking days (n, %)	77 (79.4%)	74 (79.6%)	ns
Percentage of days abstinent	79.9 <u>+</u> 31.4	77.9 <u>+</u> 30.9	ns
Secondary Outcomes			
Drinks per drinking day	3.3 <u>+</u> 5.6	3.3 <u>+</u> 4.7	ns
No relapse to heavy drinking	60 (61.9%)	52 (55.9%)	ns
Continuous Abstinence (n, %) GGT end point change	43 (44.3%)	31 (33.3%)	ns
from baseline (mean \pm SD)	-43.1 <u>+</u> 75.3	-37.9 <u>+</u> 65.7	ns

The COMBINE Study

	Good Clinical Outcome
	0⁄0
Medical Management and	
Placebo	58
Medical Management and	
Placebo and CBI	71
Medical Management and	
Naltrexone	74

CBI=Combined Behavioral Intervention Good Clinical Outcome=Abstinence or drinking moderate amounts without problems. P<0.025 (interaction p-value 0.02)

Anton RF et al. JAMA 2006 May 3;295:2003-17 (NCT00006206)

The COMBINE Study

 One year after treatment ended, the groups did not differ significantly on drinking outcomes

 Alcohol dependence is an illness that, like other chronic diseases, requires ongoing care

Substance dependence as a chronic disease

- Like other chronic conditions...
 - Genetic and environmental etiologies
 - Chronic physiologic changes
 - Relapsing course
 - No "cure"
 - Variable adherence to care
 - Medical and psychiatric comorbidity common
 - And can be triggers for relapse

Do all with the disorder need long-term treatment/is it a chronic disease for all?

- Representative sample of 43,093 U.S. adults
- Most patients with lifetime abuse or dependence had only 1 episode (72%).
 - The mean duration of dependence episodes is 2-3 years.
 - Those with >1 episode have a mean of 5 episodes.

Hasin DS, et al. Arch Gen Psychiatry. 2007;64(7):830-842.

Comorbidity

Med/Psych DX	% of AOD Pts	% of Controls
Acid-related	5.5	2.1
Arthritis	3.9	1.3
Asthma	6.8	2.6
COPD	0.7	0.1
Headache	9.2	3.8
Hypertension	7.2	3.4
Low back pain	11.2	5.8
Injury/OD	25.6	12.1
Depression	28.5	2.7
Anxiety disorder	16.9	2.2
Major psychosis	6.6	0.4
Liver cirrhosis	0.7	0.1
Hepatitis C	0.7	0.2

Mertens JR et al. Arch Intern Med 2003; 163: 2511 - 2517.

Comorbidity in a Detoxification Sample

- 470 adults with no primary medical care in a short-term residential detoxification unit, mean age 36
 - 47% had chronic medical illness
 - 90% had CES-D score >16
 - 70% reported moderate to severe pain at least intermittently during 2 years of follow-up
 - Intermittent pain associated with relapse (OR 2.0)
 - Persistent pain associated with relapse (OR 5.2)

DeAlba I et al. Am J Addictions 2004;13:33-45. Larson MJ et al. Addiction 2007; 102: 752-760. Saitz R et al. HSR 2004;39(3):587-606. Effect of Substance Use and Disorders on Comorbid Conditions

Alcohol use and medication adherence

- 22,670 patients from 7 VA Medical Centers
 - Prescribed 3 types of medications
 - Categorized by AUDIT-C as nondrinkers, low-level drinkers, and mild, moderate and severe unhealthy use
- More severe unhealthy alcohol use associated with lower adherence
- At one year, adherence was:
 - □ 66% for nondrinkers
 - G3% for those with mild unhealthy alcohol use
 - 58% for those with moderate unhealthy alcohol use
 - ^o 55% for those with severe unhealthy alcohol use

Bryson CL et al. Ann Intern Med 2008;149:795-803.

Quality of Diabetes Care

	% with retina exam
No mental disorder	71
Psychiatric disorder	71
Substance disorder	64
"Dual diagnosis"	68

Desai MM et al. Am J Psychiatry 2002;159(9): 1584-90.

Catheterization and			
Revascularization after Myocardial			
Infarction			
	CATH	PTCA	CABG
	Adjusted Relative Risk		
Mental disorder	0.72	0.75	0.68
Schizophrenia	0.41	0.55	0.27
Affective	0.65	0.51	0.63
Substance Use	0.78	0.58	0.80
No mental disorder	1	1	1

Druss BG et al. JAMA 2000; 283: 506 - 511.

Table 4. Mental Illness, Mortality, and Readmission at 1 Year^a

		Mental Illness		
	Overall	No	Yes	
Crude ^b				
All-cause readmission	69.4	68.5	73.7	
Heart failure readmission	61.3	60.6	65.2	
Mental illness readmission	11.6	7.7	31.1	
Mortality	37.0	36.2	41.0	
Adjusted				
Readmission		1 [Reference]	1.30 (1.21-1.39)	
Heart failure readmission		1 [Reference]	1.23 (1.15-1.32)	
Mental illness readmission		1 [Reference]	5.13 (4.73-5.56)	
Mortality		1 [Reference]	1.20 (1.12-1.28)	


^a Data are given as the percentage of participants and as odds ratios (95% confidence intervals) for odds of readmission or mortality among patients with mental illness compared with patients with no mental illness. ^b P<.001 for all comparisons.

ARCHIVES OF

GENERAL PSYCHIATRY

Rathore, S. S. et al. Arch Gen Psychiatry 2008;65:1402-1408.

Influence on Hepatitis C Therapy



Nunes et al. Alcohol Clin Exp Res. 2006 September; 30(9): 1520–1526.

HIV Outcomes

- Prospective cohort study of 350 adults with HIV and alcohol problems
- Depressive symptoms and substance use were associated with worse adherence
- Substance use was associated with less HIV viral load suppression
- Substance abuse treatment
 - reduced the odds of ED utilization (AOR 0.5)
 - increased the odds of HAART for HIV (AOR 1.70)
 - not associated with 30-day HAART adherence or HIV viral load suppression

Palepu A et al. J Subst Abuse Treat 2003;25:37-42 and Palepu et al. Addiction 2004;99:361-8

Death after Myocardial Infarction

	Six-month Mortality
	Adjusted Hazard Ratio (95% CI)
Depression	4.29 (3.14-5.44)

Frasure-Smith N et al. JAMA 1993;270(15):1819-1825

Current fragmented care

- Specialty substance dependence treatment focuses on use
- Variable attention to comorbidities and long-term care
- Limited coordination between medical, mental health and addictions care
- Most (82%; Green-Hennessey 2002) do not seek addiction or mental health care
- 51% do not seek care after detoxification (Mark 2002)
- About half "complete" what is usually short-term treatment (SAMHSA 2007)

Barriers to care

- Patient characteristics: Attitudes, beliefs, motivation, employment, family, psychiatric conditions
- System characteristics: Separate systems, insurance, information sharing
- Treatment program characteristics: Distance, lack of customer focus, e.g.
 - Exclusion of patient with addiction and mental health condition
 - Requirement to bring 30-day supply of medical or psychiatric medication

Specialty Treatment

- 80% primarily government funded
 - N.B. Mental Health Parity and Addiction Equity Act of 2008 signed October 3 as part of "rescue/bailout"
- 2 of 175 programs had a physician director
 - 54% have no physician
 - 34% have a part-time physician
 - 12% have a full-time physician
- 39% have a nurse
- <25% have a social worker or psychologist

NSSATS 2002, D'Aunno 2004 & McClellan AT et al. J Subst Abuse Treat 2003

Service Coordination by Severity

Integration

Addiction Specialty

Hospital, Prison, ED

Collaboration


Primary Health

Mental Health Specialty

Consultation

Mental Illness Severity

Adapted from SAMSHA 2002 Report to Congress on the Prevention and Treatment of Co-occurring Substance Abuse and Mental Disorders



Chronic Disease/Care Management

Context

- Patient-centered
- Community resources
- Chronic disease as a priority
- Elements
 - Self-management support
 - Delivery <u>system</u> design
 - Decision support
 - Clinical information systems

Wagner EH. et al. *Milbank Q* 1996; 74: 511-544.

Chronic Disease Management

- Implemented by multidisciplinary teams with disease specific skills (e.g. nurse, social worker, physician)
 - Provide care
 - Coordinate referrals
 - Communicate with other caregivers
 - Proactively follow patients
 - Facilitate access to community resources

Wagner EH. et al. *Milbank Q* 1996; 74: 511-544.

Chronic Disease Management

- Over 100 controlled trials for chronic disease management of medical and psychiatric conditions
 - Depression, congestive heart failure, asthma, arthritis, diabetes
- Disease management vs. usual care improves
 - Patient satisfaction
 - Adherence to treatment
 - Clinical and functional outcomes
 - Hospitalization (less)
 - Cost-effective
- Number of controlled trials of alcohol or drug dependence disease management: n=0

Chronic Disease Management for Substance Dependence: Case Management component

- Characteristics
 - Single contact point for assessment
 - Care planning
 - Linkage and coordination
- Outcomes
 - Increased treatment retention and receipt of treatment when needed
 - Increased medical, mental health, social service receipt
 - Decreased relapse, intoxication, medical, psychiatric, family, legal problems

Shwartz 1997; McLellan 1998, 1999; Dennis, Scott & Funk 2003

Chronic Disease Management for Substance Dependence: Integrated Care

- Delivery of primary medical care and addictions care at the same site*
- Can increase abstinence (Willenbring 1999), particularly among those with substance-related medical conditions (69% vs 55%, Weisner 2001)

*compared to usual separate care

Willenbring ML & Olson DH. Arch Intern Med 1999;159:1946-52 Willenbring ML et al. J Stud Alcohol. 1995;56:337-343 Weisner C et al. JAMA 2001;286:1715-23.

Chronic Disease Management for Substance Dependence

<u>Model Conceptual Element</u>

Community Resources


Chronic disease as priority

Self-management support

Delivery system design

Decision support <u>Clinical information systems</u> Potential Implementation Elements

Case management; address social, legal, financial needs Focus on substance dependence as chronic illness; Explicit care plans Routine assessment and feedback; Patient participation; Behavior change; Psychosocial support On-site service delivery (integrated care); Referral agreements; Planned visits; Use of non-physicians in multidisciplinary team; Patient reminders; Collaboration of addiction, medical and psychiatric physicians Specialty expertise made accessible Electronic medical record; Monitoring of outcomes



Primary Care

- Integrated and accessible health services provided by generalist clinicians
- Address the majority of healthcare needs
- Sustained patient-clinician partnership; balancing and negotiating priorities is key
- Occurs in family and community context
- Grounded in both biomedical and psychosocial sciences; physical and mental health not separate

Receipt of Primary Care Improves Addiction Severity

Table 1 Association between primary care visits and addiction outcomes in multi-variable analyses.

	Substance abuse treatment n= 391 Odds ratio, 95% CI	Alcohol severity n = 248	Drug severity n= 300	30-day drug use or use of alcohol to intoxication n= 391 Odds ratio, 95% CI
Primary care visits during 6 months		Predicted mean ASI score	Predicted mean ASI score	
0	_	0.34	0.16	_
1	1.08(0.70 - 1.67)	0.26	0.15	0.91 (0.54-1.52)
≥2	1.04(0.73 - 1.49)	0.30	0.13	0.45 (0.29-0.69)
P-value	P = 0.94	P = 0.04	P = 0.01	P = 0.002

Care for People with Drug Abuse or Dependence

	Hospitalization
	(AOR, 95% CI)
HIV	
Regular* drug care	0.85 (0.76-0.96)
Regular med care	0.82 (0.74-0.91)
Both	0.76 (0.67-0.85)
Non-HIV	
Regular drug care	0.71 (0.66-0.76)
Regular med care	0.91 (0.86-0.95)
Both	0.73 (0.68-0.79)

Laine C et al. JAMA 2001; 285: 2355 - 2362. *Regular=one source of care over time

PCMH: Patient Centered Medical Home

- Excellent healthcare based on a trusting relationship with a personal physician who provides first contact and continuous comprehensive care
 - A team
 - Patient-centered (respectful and responsive to individual preferences and values)
 - Prevention/check-ups, coordination/consultation, accessible (hours, open access)

The Patient-Centered Primary Care Collaborative www.pcpcc.net Medical Home Demonstration project (2009) is mandated by Congress through the Tax Relief and Health Care Act of 2006 (TRHCA).

TODAY'S CARE

My patients are those who make appointments to see me

Patients' chief complaints or reasons for visit determines care

Care is determined by today's problem and time available today

Care varies by scheduled time and memory or skill of the doctor

Patients are responsible for coordinating their own care

I know I deliver high quality care because I'm well trained

Acute care is delivered in the next available appointment and walk-ins

It's up to the patient to tell us what happened to them

Clinic operations center on meeting the doctor's needs

MEDICAL HOME CARE

Our patients are those who are registered in our medical home

We systematically assess all our patients' health needs to plan care

Care is determined by a proactive plan to meet patient needs without visits

Care is standardized according to evidence-based guidelines

A prepared team of professionals coordinates all patients' care

We measure our quality and make rapid changes to improve it

Acute care is delivered by open access and non-visit contacts

We track tests & consultations, and follow-up after ED & hospital

A multidisciplinary team works at the top of our licenses to serve patients

Slide from Daniel Duffy MD School of Community Medicine Tulsa Oklahoma

Confidentiality: CFR 42, Part 2

- (a) An individual or entity (<u>other than a general medical care</u> <u>facility</u>) <u>who holds itself out</u> as providing, <u>and</u> provides, alcohol or drug abuse diagnosis, treatment or referral for treatment; or
- (b) <u>An identified unit within a general medical facility</u> <u>which holds itself out</u> as providing, and provides, alcohol or drug abuse diagnosis, treatment or referral for treatment; or
- (c) Medical personnel or other staff in a general medical care facility whose **primary function** is the provision of alcohol or drug abuse diagnosis, treatment or referral for treatment and who are identified as such providers. (See §2.12(e)(1) for examples.)

http://www.access.gpo.gov/nara/cfr/waisidx_02/42cfr2_02.html

Confidentiality: CFR 42, Part 2

• Does it apply?

- I am a doctor, not a lawyer; this is not legal advice
- Primary care services usually do not "hold themselves out as..." nor is their "primary function..."
- If so, releases (PCP \leftarrow >specialist)
 - Communication with PCP similar to other specialists
 - Patient safety, quality of care rely on such communication
 - e.g. methadone and QTc

Addiction Health Evaluation and Disease management (AHEAD) study: Design

 Randomized controlled trial of the effectiveness of alcohol and/or drug dependence chronic disease management in primary care, with 3, 6, and 12 month in-person follow-up (and 2 year healthcare utilization follow-up)



AHEAD study: CDM Intervention

Systems components

- RN care manager, MDs (internist with alcohol/drug expertise, psychiatrist), SW, <u>in primary care</u>
- Linkage with city addiction treatment services
- Use of electronic record
- Coordination of care with PCP and specialty treatment services (phone, EMR, info. releases)
- Reminders



AHEAD study: CDM Intervention

Medical, psychiatric, social components

- Assessments, address short term needs, prioritize, refer, ongoing social work assistance
- Substance dependence-specific components
 - Negotiate treatment plan
 - MET
 - Relapse prevention, primary care adaptation
 - Offer naltrexone, acamprosate, disulfiram, or buprenorphine; medication management
 - Offer referral to mutual help groups and specialty treatment
 - Re-entry to care after relapse




AHEAD study: Intervention

AHEAD Assessment

Linkage

AHEAD Unit Initial Intervention (2 visits)

✤Initiate alcohol treatment ✤Initiate medical treatment ✤Linkage to primary care ✤Additional treatment *Referrals



AHEAD Study: Preliminary data



Conclusions


- Alcohol, and maybe drug, screening and brief intervention effective in primary care
- Management of unhealthy substance use in primary care (including counseling, medication and referral) is feasible and efficacious
- Substance dependence is sometimes a chronic disease, often accompanied by co-occurring conditions that affect each other
- Chronic disease management is an approach that has promise for improving treatment for substance dependence
- Preliminary data suggest that patients with substance dependence appear to be willing to initiate and engage with chronic disease management/addiction care

Leading Causes of Preventable Death in the US

Cause	Number	% of all deaths
Tobacco	435,000	18.1
Diet/Activity	400,000	16.6
Alcohol	85,000	3.5
Illicit drugs	17,000	0.7
Total deaths	2,403,351	

>50% of alcohol deaths due to INJURY
2.3 million years of potential life lost (30/each alcohol related deaths)
Mokdad AH et al. JAMA 2004;291:1238-1245. Midanik LT et al. MMWR 2004;53:866

Attributable Preventable Burden of Disease in Developed Countries



% Total Number of Health Years Lost to Death/Disability

Screening and Brief Intervention: Among the most effective and costeffective preventive services

- Grouped according to health impact and costeffectiveness
 - 10: Aspirin chemoprophylaxis, childhood immunizations,
 tobacco use screening and brief intervention
 - 9: Unhealthy alcohol use screening and brief intervention
 - Cost-saving for society; \$1755 per QALY (health system)
 - 8: Colorectal cancer screening, hypertension screening, influenza vaccination, pneumococcal vaccination, vision screening

Solberg LI et al. Am J Prev Med 2008; 34(2): 143-152. Maciosek MV et al. Am J Prev Med 2006; 31(1):52-61. **Bold** indicates <50% of eligible population receiving the service.

AUDIT



• Alcohol Use Disorders Identification Test (AUDIT)

- 10 items, consumption and consequences
- Positive score ≥ 8 for men, ≥ 4 for women, elderly
- 57-95% sensitive, 78-96% specific
- AUDIT-C
 - First 3 items of AUDIT (consumption only)
 - Positive score \geq 4 for men, \geq 3 for women
 - Similar operating characteristics

Fiellin DA, O'Connor PG. Ann Intern Med 2000;133:815-27

AUDIT



- How often do you have a drink containing alcohol?
- How many drinks containing alcohol do you have on a typical day when you are drinking?
- How often do you have 6 (4/5) or more drinks on one occasion?
- How often during the last year have you found that you were not able to stop drinking once you had started?
- How often during the last year have you failed to do what was normally expected from you because of drinking?
- How often during the last year have you been unable to remember what happened the night before because you had been drinking?
- Have you or someone else been injured as a result of your drinking?
- How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?
- How often during the last year have you had a feeling of guilt or remorse after drinking?
- Has a relative, friend, doctor, or other health worker been concerned about your drinking or suggested that you should cut down?

Alcohol-related Diagnoses, AAFs<1

Pulmonary and other respiratory tuberculosis 0.2	25
Malignant neoplasm of lip, oral cavity, and pharynx 0.	50
Malignant neoplasm of esophagus 0.	75
Malignant neoplasm of stomach 0.2	20
Malignant neoplasm of liver + intrahepatic bile ducts 0.	15
Malignant neoplasm of larynx 0.	50
Diabetes mellitus 0.	05
Essential hypertension 0.	076
Cerebrovascular disease 0.	065
Pneumonia and influenza 0.	05
Diseases of esophagus, stomach, and duodenum 0.	10
Cirrhosis of liver without mention of alcohol 0.	50
Biliary cirrhosis 0.	50
Acute pancreatitis 0.	42
Chronic pancreatitis 0.	60

Medical Disorders More Common in Patients with Substance Use Disorder, Psychotic Disorder, and Both

- Diabetes
- Hypertension
- Heart Disease*
- Asthma*
- Gastrointestinal Disorders*
- Skin Infections*
- Malignant Neoplasms
- Acute Respiratory Disorders*

*highest risk in those with both Dickey B et al. Psych Services 2002;53(7):861-7.

Integrated Medical and Alcoholism Care

- Randomized trial of a thorough multidisciplinary evaluation, and care plan (N=101)
- Monthly primary care visits to review drinking and medical problems
- Mental health, social services and more intensive alcohol treatment on site
- 2-year results:
 - 30-day abstinence increased from 47% to 74%
 - Mortality decreased from 30% to 19%

Willenbring ML & Olson DH. Arch Intern Med 1999;159:1946-52 Willenbring ML et al. J Stud Alcohol. 1995;56:337-343 Receipt of Primary Care Improves Addiction Severity, particularly among those with worse physical health

	Predicted mean differences in drug addiction severity		
	Sample mean - 2 SE	Sample mean	Sample mean + 2 SE
Receipt of primary care	PCS = 26	PCS = 48	PCS = 70
No primary care visits	-0.08	-0.15	-0.21
1 visit	-0.19	-0.18	-0.19
≥2 visits	-0.16	-0.19	-0.23

Buprenorphine Efficacy




Table 3. Eligibility and Treatment by Quality Indicators^a

		Menta	al Illness	
	Overall	No	Yes	<i>P</i> Value
Patients classified as ideal candidates				
Prescribed ACE inhibitors ^b	16.4	16.7	15.3	.02
Documentation of left ventricular systolic function	98.2	98.2	98.3	.12
Treatment among ideal candidates				
Prescribed ACE inhibitors	71.0	71.3	69.7	.40
Prescribed ACE inhibitors or ARBs	79.5	79.7	78.5	.47
Documentation of left ventricular systolic function	52.0	53.0	47.3	<.001
Adjusted odds of treatment among ideal candidates				
Prescribed ACE inhibitors		1 [Reference]	0.96 (0.80-1.14)	.61
Prescribed ACE inhibitors or ARBs		1 [Reference]	0.95 (0.78-1.17)	.64
Documentation of left ventricular systolic function		1 [Reference]	0.81 (0.76-0.87)	<.001

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.

^a Data are presented as the percentage of participants and as adjusted odds ratios (95% confidence intervals) for receipt of quality indicator among patients with mental illness compared with patients without mental illness.

^bSame cohort for the evaluation of the prescription of ACE inhibitors or ARBs.

Rathore, S. S. et al. Arch Gen Psychiatry 2008;65:1402-1408.

ARCHIVES OF GENERAL PSYCHIATRY

Treating Major Depression in Patients with Myocardial Infarction

- Randomized, clinical trial
- 2,481 men and women hospitalized with MI and depression (75%) or lower perceived social support (25%)
- CBT and group therapy for 6 months
- Results:
 - Improvements in depressive symptoms and perceived social support
 - No difference in 24% death or recurrent MI

Chronic Disease Management (CDM)

- Example: Depression RCT, CDM v. usual care
- 1,801 depressed older adults, 18 primary care clinics
- CDM
 - Patient education
 - Visit with a trained depression nurse or psychologist in primary care
 - Team development of care plans
 - Work with primary care physicians, make referrals
 - Offer of medication or brief psychotherapy
 - Frequent follow-up visits and phone contacts
- CDM patients were more likely to
 - Receive depression treatments
 - Have reduction in depressive symptoms and functional impairment
 - Have improved arthritis pain and function

Unutzer et al. J Am Geriatr Soc 2004; 52: 1916-1922.

AHEAD study: Intervention Structure

- Assessment (alcohol/drug, medical, social, psychological)
- Initial intervention (over 2 visits)
 - Feedback
 - Preventive services
 - Initiation of alcoholism treatment
 - Initiation of medical treatment
 - Referral to primary medical care
 - Additional treatment and referrals
- Continuing care
 - RN care manager contacts, ongoing facilitated referrals, availability for drop-in care

